GRANULES

- Granules India has submitted a Paragraph IV certification for Ruxolitinib Extended-Release Tablets ANDA. - The company believes it is eligible for potential sole first-to-file status, which could provide 180 days of generic drug exclusivity. - The filing remains subject to US FDA review and determination.